Oral MucoRice expressing double-mutant cholera toxin A and B subunits induces toxin-specific neutralising immunity

Vaccine

Volumn 27, Issue 43, 2009, Pages 5982-5988

  Yuki, Yoshikazu ^a   Tokuhara, Daisuke ^a   Nochi, Tomonori ^a   Yasuda, Hiroshi ^b   Mejima, Mio ^a   Kurokawa, Shiho ^a   Takahashi, Yuko ^a   Kataoka, Nobuhiro ^a   Nakanishi, Ushio ^a   Hagiwara, Yukari ^c   Fujihashi, Kohtaro ^d   Takaiwa, Fumio ^e   Kiyono, Hiroshi ^a,d  

^a UNIVERSITY OF TOKYO   (Japan)

^b NATIONAL AGRICULTURAL RESEARCH CENTER FOR HOKKAIDO REGION   (Japan)

^c KITASATO INSTITUTE   (Japan)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e NATIONAL INSTITUTE OF AGROBIOLOGICAL SCIENCES   (Japan)

Author keywords

Cholera; Cold chain free; MucoRice; Mutant cholera toxin; Oral vaccine; Rice based vaccine

Indexed keywords

CHOLERA TOXIN; CHOLERA VACCINE; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; MUCORICE CTB; MUCORICE DMCTA; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY DEPENDENT ENHANCEMENT; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; DRUG POTENCY; DRUG SYNTHESIS; GENE EXPRESSION SYSTEM; IMMUNOREACTIVITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RICE; TRANSGENE; TRANSGENIC CROP; WESTERN BLOTTING;

ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODY FORMATION; BACTERIAL VACCINES; CHOLERA TOXIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; ORYZA SATIVA; PLANTS, GENETICALLY MODIFIED;

EID: 70349292095     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.07.071     Document Type: Article

References (21)

1. Streatfield S.J., Jilka J.M., Hood E.E., Turner D.D., Bailey M.R., Mayor J.M., et al. Plant-based vaccines: unique advantages. Vaccine 19 17-19 (2001) 2742-2748
2. Streatfield S.J., and Howard J.A. Plant-based vaccines. Int J Parasitol 33 5-6 (2003) 479-493
3. Nochi T., Takagi H., Yuki Y., Yang L., Masumura T., Mejima M., et al. Rice-based mucosal vaccine as a global strategy for cold-chain- and needle-free vaccination. Proc Natl Acad Sci USA 104 26 (2007) 10986-10991
4. Takagi H., Hiroi T., Yang L., Tada Y., Yuki Y., Takamura K., et al. A rice-based edible vaccine expressing multiple T cell epitopes induces oral tolerance for inhibition of Th2-mediated IgE responses. Proc Natl Acad Sci USA 102 48 (2005) 17525-17530
5. Yamamoto S., Takeda Y., Yamamoto M., Kurazono H., Imaoka K., Fujihashi K., et al. Mutants in the ADP-ribosyltransferase cleft of cholera toxin lack diarrheagenicity but retain adjuvanticity. J Exp Med 185 7 (1997) 1203-1210
6. Hagiwara Y., Kawamura Y.I., Kataoka K., Rahima B., Jackson R.J., Komase K., et al. A second generation of double mutant cholera toxin adjuvants: enhanced immunity without intracellular trafficking. J Immunol 177 5 (2006) 3045-3054
7. Mekalanos J.J., Swartz D.J., Pearson G.D., Harford N., Groyne F., and de Wilde M. Cholera toxin genes: nucleotide sequence, deletion analysis and vaccine development. Nature 306 5943 (1983) 551-557
8. Qu le Q., and Takaiwa F. Evaluation of tissue specificity and expression strength of rice seed component gene promoters in transgenic rice. Plant Biotechnol J 2 2 (2004) 113-125
9. Goto F., Yoshihara T., Shigemoto N., Toki S., and Takaiwa F. Iron fortification of rice seed by the soybean ferritin gene. Nat Biotechnol 17 3 (1999) 282-286
10. Hiei Y., Ohta S., Komari T., and Kumashiro T. Efficient transformation of rice (Oryza sativa L.) mediated by Agrobacterium and sequence analysis of the boundaries of the T-DNA. Plant J 6 2 (1994) 271-282
11. Yuki Y., Byun Y., Fujita M., Izutani W., Suzuki T., Udaka S., et al. Production of a recombinant hybrid molecule of cholera toxin-B-subunit and proteolipid-protein-peptide for the treatment of experimental encephalomyelitis. Biotechnol Bioeng 74 1 (2001) 62-69
12. Kweon M.N., Yamamoto M., Watanabe F., Tamura S., Van Ginkel F.W., Miyauchi A., et al. A nontoxic chimeric enterotoxin adjuvant induces protective immunity in both mucosal and systemic compartments with reduced IgE antibodies. J Infect Dis 186 9 (2002) 1261-1269
13. Arakawa T., Yu J., Chong D.K., Hough J., Engen P.C., and Langridge W.H. A plant-based cholera toxin B subunit-insulin fusion protein protects against the development of autoimmune diabetes. Nat Biotechnol 16 10 (1998) 934-938
14. Kothary M.H., Claverie E.F., Miliotis M.D., Madden J.M., and Richardson S.H. Purification and characterization of a Chinese hamster ovary cell elongation factor of Vibrio hollisae. Infect Immun 63 7 (1995) 2418-2423
15. Agren L.C., Ekman L., Lowenadler B., Nedrud J.G., and Lycke N.Y. Adjuvanticity of the cholera toxin A1-based gene fusion protein, CTA1-DD, is critically dependent on the ADP-ribosyltransferase and Ig-binding activity. J Immunol 162 4 (1999) 2432-2440
16. Lycke N., Erlandsson L., Ekman L., Schon K., and Leanderson T. Lack of J chain inhibits the transport of gut IgA and abrogates the development of intestinal antitoxic protection. J Immunol 163 2 (1999) 913-919
17. Hill D.R., Ford L., and Lalloo D.G. Oral cholera vaccines: use in clinical practice. Lancet Infect Dis 6 6 (2006) 361-373
18. Giudice E.L., and Campbell J.D. Needle-free vaccine delivery. Adv Drug Deliv Rev 58 1 (2006) 68-89
19. Varmus H., Klausner R., Zerhouni E., Acharya T., Daar A.S., and Singer P.A. Public health. Grand challenges in global health. Science 302 5644 (2003) 398-399
20. Marinaro M., Staats H.F., Hiroi T., Jackson R.J., Coste M., Boyaka P.N., et al. Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4. J Immunol 155 10 (1995) 4621-4629
21. Yamamoto S., Kiyono H., Yamamoto M., Imaoka K., Fujihashi K., Van Ginkel F.W., et al. A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity. Proc Natl Acad Sci USA 94 10 (1997) 5267-5272